Comparison of Collaborative Goal Setting With Enhanced Education for Managing Diabetes-Associated Distress and Hemoglobin A1c Levels: A Randomized Clinical Trial.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
Type 2 diabetes is a prevalent and morbid condition. Poor engagement with self-management can contribute to diabetes-associated distress and hinder diabetes control. To evaluate the implementation and effectiveness of Empowering Patients in Chronic Care (EPICC), an evidence-based intervention to improve diabetes-associated distress and hemoglobin A1c (HbA1c) levels after the intervention and after 6-month maintenance. This hybrid (implementation-effectiveness) randomized clinical trial was performed in Veterans Affairs clinics across Illinois, Indiana, and Texas from July 1, 2015, to June 30, 2017. Participants included adults with uncontrolled type 2 diabetes (HbA1c level >8.0%) who received primary care during the prior year in participating clinics. Data collection was completed on November 30, 2018, and data analysis was completed on June 30, 2020. All analyses were based on intention to treat. Participants in EPICC attended 6 group sessions based on a collaborative goal-setting theory led by health care professionals. Clinicians conducted individual motivational interviewing sessions after each group. Usual care was enhanced (EUC) with diabetes education. The primary outcome consisted of changes in HbA1c levels after the intervention and during maintenance. Secondary outcomes included the Diabetes Distress Scale (DDS), Morisky Medication Adherence Scale, and Lorig Self-efficacy Scale. Secondary implementation outcomes included reach, adoption, and implementation (number of sessions attended per patient). A total of 280 participants with type 2 diabetes (mean [SD] age, 67.2 [8.4] years; 264 men [94.3]; 134 non-Hispanic White individuals [47.9%]) were equally randomized to EPICC or EUC. Participants receiving EPICC had significant postintervention improvements in HbA1c levels (F1, 252 = 9.12, Cohen d = 0.36 [95% CI, 0.12-0.59]; P = .003) and DDS (F1, 245 = 9.06, Cohen d = 0.37 [95% CI, 0.13-0.60]; P = .003) compared with EUC. During maintenance, differences between the EUC and EPICC groups remained significant for DDS score (F1, 245 = 8.94, Cohen d = 0.36 [95% CI, 0.12-0.59]; P = .003) but not for HbA1c levels (F1, 252 = 0.29, Cohen d = 0.06 [95% CI, -0.17 to 0.30]; P = .60). Improvements in DDS scores were modest. There were no differences between EPICC and EUC in improvements after intervention or maintenance for either adherence or self-efficacy. Among all 4002 eligible patients, 280 (7.0%) enrolled in the study (reach). Each clinic conducted all planned EPICC sessions and cohorts (100% adoption). The EPICC group participants attended a mean (SD) of 4.34 (1.98) sessions, with 54 (38.6%) receiving all 6 sessions. A patient-empowerment approach using longitudinal collaborative goal setting and motivational interviewing is feasible in primary care. Improvements in HbA1c levels after the intervention were not sustained after maintenance. Modest improvements in diabetes-associated distress after the intervention were sustained after maintenance. Innovations to expand reach (eg, telemedicine-enabled shared appointments) and sustainability are needed. ClinicalTrials.gov Identifier: NCT01876485.
Identifiants
pubmed: 35507345
pii: 2791850
doi: 10.1001/jamanetworkopen.2022.9975
pmc: PMC9069258
doi:
Substances chimiques
Glycated Hemoglobin A
0
Banques de données
ClinicalTrials.gov
['NCT01876485']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e229975Références
JAMA Cardiol. 2016 Apr 1;1(1):9-10
pubmed: 27437646
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Diabet Med. 2009 Jun;26(6):622-7
pubmed: 19538238
Perm J. 2014 Winter;18(1):90-1
pubmed: 24626077
J Altern Complement Med. 2019 Mar;25(S1):S7-S11
pubmed: 30870023
Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84
pubmed: 33298417
Diabet Med. 2018 Jun 13;:
pubmed: 29896760
Chronic Illn. 2016 Dec;12(4):261-271
pubmed: 27153858
Diabetes Care. 2005 Mar;28(3):626-31
pubmed: 15735199
J Am Geriatr Soc. 2018 Oct;66(10):1872-1879
pubmed: 30281794
Diabet Med. 2019 Jul;36(7):803-812
pubmed: 30985025
Am J Med. 2004 Feb 1;116(3):186-7
pubmed: 14749163
Diabet Med. 2020 May;37(5):805-813
pubmed: 31872457
BMJ Open. 2018 Jan 21;8(1):e018093
pubmed: 29358425
Milbank Q. 2011 Sep;89(3):399-424
pubmed: 21933274
J Aging Health. 2021 Aug-Sep;33(7-8):469-481
pubmed: 33555233
Patient Educ Couns. 2008 Sep;72(3):418-23
pubmed: 18621501
Ann Intern Med. 2013 Feb 5;158(3):169-78
pubmed: 24779044
Patient Educ Couns. 2013 Jul;92(1):94-9
pubmed: 23433777
J Am Geriatr Soc. 2012 Feb;60(2):193-201
pubmed: 22260627
JAMA Intern Med. 2019 Oct 07;:
pubmed: 31589281
Am J Bioeth. 2014;14(6):1-3
pubmed: 24809597
Endocrinol Diabetes Metab. 2019 Nov 18;3(1):e00099
pubmed: 31922026
Patient Educ Couns. 2006 Oct;63(1-2):145-51
pubmed: 16406471
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Diabetes Educ. 2020 Apr;46(2):139-160
pubmed: 31928334
Circulation. 2008 Mar 18;117(11):1361-8
pubmed: 18316489
Arch Intern Med. 2011 Mar 14;171(5):453-9
pubmed: 21403042
Front Public Health. 2019 Mar 29;7:64
pubmed: 30984733
JAMA Netw Open. 2021 Mar 1;4(3):e211271
pubmed: 33760091
Fam Pract. 2015 Apr;32(2):216-23
pubmed: 25552674
Diabet Med. 2020 Mar;37(3):393-400
pubmed: 31638279
J Am Geriatr Soc. 2016 Mar;64(3):625-31
pubmed: 27000335